192 related articles for article (PubMed ID: 26266640)
1. Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer.
Kaira K; Sunaga N; Imai H; Kamide Y; Koga Y; Ono A; Kuwako T; Masuda T; Hisada T; Ishizuka T; Yamada M
Int J Clin Oncol; 2016 Apr; 21(2):240-247. PubMed ID: 26266640
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402.
Nogami N; Hotta K; Segawa Y; Takigawa N; Hosokawa S; Oze I; Fujii M; Ichihara E; Shibayama T; Tada A; Hamada N; Uno M; Tamaoki A; Kuyama S; Ikeda G; Osawa M; Takata S; Tabata M; Tanimoto M; Kiura K
Acta Oncol; 2012 Jul; 51(6):768-73. PubMed ID: 22283472
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer.
Chihara Y; Date K; Takemura Y; Tamiya N; Kohno Y; Imabayashi T; Kaneko Y; Yamada T; Ueda M; Arimoto T; Uchino J; Iwasaki Y; Takayama K
Invest New Drugs; 2019 Apr; 37(2):291-296. PubMed ID: 30121935
[TBL] [Abstract][Full Text] [Related]
4. A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer.
Kaira K; Tsuchiya S; Sunaga N; Yanagitani N; Watanabe S; Imai H; Hisada T; Ishizuka T; Saito R; Mori M
Am J Clin Oncol; 2007 Feb; 30(1):51-6. PubMed ID: 17278895
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).
Kaneda H; Okamoto I; Hayashi H; Yoshioka H; Miyazaki M; Kudoh S; Kimura T; Sugiura T; Sawa T; Takeda K; Iwamoto Y; Satouchi M; Akita K; Saito H; Goto I; Shibata K; Fukuoka M; Nakagawa K;
J Thorac Oncol; 2010 Jan; 5(1):105-9. PubMed ID: 19884859
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
Otani S; Hamada A; Sasaki J; Wada M; Yamamoto M; Ryuge S; Takakura A; Fukui T; Yokoba M; Mitsufuji H; Toyooka I; Maki S; Kimura M; Hayashi N; Ishihara M; Kasajima M; Hiyoshi Y; Katono K; Asakuma M; Igawa S; Kubota M; Katagiri M; Saito H; Masuda N
Am J Clin Oncol; 2015 Aug; 38(4):405-10. PubMed ID: 26214085
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of amrubicin and fixed dose of irinotecan (CPT-11) in relapsed small cell lung cancer: Japan multinational trial organization LC0303.
Kawahara M; Kubo A; Komuta K; Fujita Y; Sasaki Y; Fukushima M; Daimon T; Furuse K; Mishima M; Mio T
J Thorac Oncol; 2012 Dec; 7(12):1845-1849. PubMed ID: 22139390
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation and feasibility study of amrubicin combined with cisplatin in previously untreated patients with advanced non-small cell lung cancer.
Yoshimura N; Kimura T; Mitsuoka S; Kyoh S; Tochino Y; Asai K; Ichimaru Y; Hirata K; Kudoh S
Am J Clin Oncol; 2013 Apr; 36(2):105-9. PubMed ID: 22270109
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial.
Kitagawa C; Saka H; Kajikawa S; Mori K; Oki M; Suzuki R
Cancer Chemother Pharmacol; 2012 May; 69(5):1379-85. PubMed ID: 22237957
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer.
Inoue A; Yamazaki K; Maemondo M; Suzuki T; Kimura Y; Kanbe M; Isobe H; Nishimura M; Saijo Y; Nukiwa T
J Thorac Oncol; 2006 Jul; 1(6):551-5. PubMed ID: 17409916
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
12. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
[TBL] [Abstract][Full Text] [Related]
14. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer.
Sugiura T; Ariyoshi Y; Negoro S; Nakamura S; Ikegami H; Takada M; Yana T; Fukuoka M
Invest New Drugs; 2005 Aug; 23(4):331-7. PubMed ID: 16012792
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer.
Masuda N; Matsui K; Negoro S; Takeda K; Kudoh S; Nakagawa K; Mukaiyama A; Arase H; Yoshida P; Ijima T; Takada M; Fukuoka M
Clin Lung Cancer; 2010 Jul; 11(4):271-9. PubMed ID: 20630830
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Fukuda M; Nakamura Y; Kasai T; Nagashima S; Nakatomi K; Doi S; Nakano H; Takatani H; Fukuda M; Kinoshita A; Soda H; Tsukamoto K; Oka M; Kohno S;
J Thorac Oncol; 2009 Jun; 4(6):741-5. PubMed ID: 19404211
[TBL] [Abstract][Full Text] [Related]
19. A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer.
Kubota K; Sakai H; Yamamoto N; Kunitoh H; Nakagawa K; Takeda K; Ichinose Y; Saijo N; Ariyoshi Y; Fukuoka M
J Thorac Oncol; 2010 May; 5(5):702-6. PubMed ID: 20150827
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
